ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

AcelRx Pharmaceuticals, Inc. (the Company or AcelRx) will be
providing financial information about the Companys cash and
outstanding loan balances as of December31, 2016 in the Companys
presentation handout to be utilized in various meetings with
securities analysts and investors during the J.P. Morgan
Healthcare Conference from January9, 2017 through January12, 2017
in San Francisco, and The Trout Group Annual 1×1 Management
Access Event from January 10, 2017 through January 13, 2017, also
in San Francisco. The aforementioned financial information is
included on slides #36 and #39 of the presentation handout, as
furnished in Exhibit 99.1 to this Current Report and is
incorporated herein by reference.

The information contained in this Item2.02 and in the
accompanying Exhibit 99.1 to this Current Report shall be deemed
to be furnished and shall not be deemed to be filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended (the Securities Act). The information contained
in this Item2.02 and in the accompanying Exhibit 99.1 to this
Current Report shall not be incorporated by reference into any
filing with the U.S. Securities and Exchange Commission under the
Securities Act or the Exchange Act made by the Company, whether
made before or after the date hereof, regardless of any general
incorporation language in such filing.

Item 7.01. Regulation FD
Disclosure.

AcelRx will participate in various meetings with securities
analysts and investors during the J.P. Morgan Healthcare
Conference from January9, 2017 through January12, 2017 in San
Francisco, and The Trout Group Annual 1×1 Management Access Event
from January 10, 2017 through January 13, 2017, also in San
Francisco, and will utilize a presentation handout during those
meetings. The presentation handout, together with a slide setting
forth certain cautionary language intended to qualify the
forward-looking statements included in the presentation handout,
are furnished as Exhibit 99.1 to this Current Report and are
incorporated herein by reference. The presentation handout will
also be made available in the Investor Relations section of
AcelRx Pharmaceuticals, Inc.s website, located at www.acelrx.com.

The information contained in this Item7.01 and in the
accompanying Exhibit 99.1 to this Current Report shall be deemed
to be furnished and shall not be deemed to be filed for purposes
of Section18 of the Exchange Act, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act. The information contained in this Item7.01 and in
the accompanying Exhibit 99.1 to this Current Report shall not be
incorporated by reference into any filing with the U.S.
Securities and Exchange Commission under the Securities Act or
the Exchange Act made by the Company, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.

Item .01. Other Events.

On January 8, 2017, the Company issued a press release entitled
AcelRx Pharmaceuticals Announces DSUVIA as Brand Name for ARX-04
a copy of which is attached as Exhibit 99.2 to this Report.

Also on January 8, 2017, the Company issued a press release
entitled AcelRx Pharmaceuticals Provides Guidance on 2017
Milestones for ARX-04, now known as DSUVIA in the United States,
for the Treatment of Moderate-to-Severe Acute Pain a copy of
which is attached as Exhibit 99.3 to this Report.

(d) Exhibits.

About ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) Recent Trading Information

ACELRX PHARMACEUTICALS, INC. (NASDAQ:ACRX) closed its last trading session down -0.05 at 2.60 with 200,771 shares trading hands.